Liafensine Explained

Liafensine (BMS-820836) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) which was under development by Bristol-Myers Squibb for the treatment of major depressive disorder.^{[1] [2]} Though it demonstrated comparable effectiveness to escitalopram and duloxetine in phase II clinical trials, development was paused in 2013 because liafensine failed to show superior effectiveness relative to these drugs, a decision that was made likely based on its increased capacity for side effects as well as potential for abuse. Another clinical trial of liafensine began in 2022.^[3]

See also

• Amitifadine
• Ansofaxine

Notes and References

1. Digest. Progress in Neurology and Psychiatry. 17. 5. 2013. 41–43. 1367-7543. 10.1002/pnp.305. 222168896. free.
2. Book: Bang-Andersen B, Bøgesø KP, Kehler J, Sánchez C . New Trends in Antidepressant Drug Research . Ecker GF, Clausen RP, Sitte HH . Transporters as drug targets . Methods and Principles in Medicinal Chemistry . 2017 . Weinheim, Germany . John Wiley & Sons . 10.1002/9783527679430.ch2 . 978-3-527-33384-4 . https://books.google.com/books?id=uRauDQAAQBAJ&dq=Liafensine&pg=PA35 . 21–52 (22) .
3. Web site: CTG Labs - NCBI . clinicaltrials.gov . 3 December 2023.